NCT06277765View on ClinicalTrials.gov

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

January 23, 2025

Study Completion Date

January 23, 2025

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

CM310

Interleukin-4 receptor(IL-4Rα) monoclonal antibody

OTHER

placebo

Placebo

Trial Locations (1)

Unknown

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06277765 - Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis | Biotech Hunter | Biotech Hunter